Please use this identifier to cite or link to this item:
Title: Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis
Authors: Bhatia, M. 
Landolfi, C.
Basta, F.
Bovi, G.
Ramnath, R.D. 
De Joannon, A.C.
Guglielmotti, A.
Keywords: Bindarit
Issue Date: Oct-2008
Citation: Bhatia, M., Landolfi, C., Basta, F., Bovi, G., Ramnath, R.D., De Joannon, A.C., Guglielmotti, A. (2008-10). Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. Inflammation Research 57 (10) : 464-471. ScholarBank@NUS Repository.
Abstract: Objective: Chemokines play a fundamental role in trafficking and activation of leukocytes in colonic inflammation. We investigated the ability of bindarit, an inhibitor of monocyte chemoattractant protein-1 (MCP-1/CCL2) synthesis, to inhibit chemokine production by human intestinal epithelial cells (HT-29) and its effect in trinitro-benzene sulfonic acid (TNBS)-induced colitis in mice. Materials and Methods: HT-29 cells were incubated with bindarit in the presence of TNF-α/IFN-γ and 24 h later supernatants were collected for MCP-1, IL-8 and RANTES measurement. A 1 mg enema of TNBS was given to BALB/c mice, and bindarit (100 mg/kg) was orally administered twice daily starting from two days before colitis induction. Weight loss, histology, and MCP-1 level and myeloperoxidase (MPO) activity in colon extracts were assessed. Results: In HT-29 cells, bindarit concentration-dependently and selectively inhibited MCP-1 secretion (as well as mRNA expression) primed by TNF-α/IFN-γ. Moreover treatment with bindarit reduced clinical and histopathological severity of TNBS-induced colitis. These effects were associated with significant inhibition of MCP-1 and MPO in colon extracts. Conclusions: Bindarit exhibits a potent bioactivity in reducing leukocyte infiltration, down-regulating MCP-1 synthesis, and preventing the development of severe colitis in a mice model of TNBS-induced colitis. These observations suggest a potential use of MCP-1 synthesis blockers in intestinal inflammation in humans. © 2008 Birkhäuser Verlag.
Source Title: Inflammation Research
ISSN: 10233830
DOI: 10.1007/s00011-008-7210-y
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Jul 5, 2022


checked on Jul 5, 2022

Page view(s)

checked on Jun 23, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.